

CELESTIAL BIOLABS LIMITED
Plot No.59, Road No.12, TSIC Tech Park, IDA Nacharam, Hyderabad-500 076
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2019

SL.NO.	PARTICULARS	Rs In lacs			
		Quarter Ended		Year Ended	
		30.06.2019 (Unaudited)	31.03.2019 (Audited)	30.06.2018 (Unaudited)	31.03.2019 (Audited)
I	a) Revenue from operations	427.12	298.00	1,669.18	4,897.42
II	b) Other Income	1.26	34.95	-	35.65
III	Total income (I+II)	428.38	332.95	1,669.18	4,933.07
IV	Expenditure				
	a) Cost of raw and packing materials consumed	0.86	17.16	24.49	51.40
	b) Purchase of Traded Products	268.18	145.56	787.81	3,070.24
	c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	(19.16)	(411.81)	59.98	(251.56)
	d) Employee Benefits Expense	19.44	17.86	29.52	148.19
	e) Depreciation and amortization	222.04	370.71	192.58	944.13
	g) Finance Cost	14.18	97.09	0.05	125.05
	h) Other Expenses	22.76	150.25	447.58	705.27
	Total expenses	528.30	386.82	1,542.01	4,792.71
V	Profit / (Loss) before exceptional items and Tax (III-IV)	(99.92)	(53.87)	127.17	140.36
VI	Exceptional items	-	-	-	-
VII	Profit / (Loss) before tax (V-VI)	(99.92)	(53.87)	127.17	140.36
VIII	Tax expense	-	-	-	(143.17)
IX	Net Profit / (Loss) for the period (VII-VIII)	(99.92)	(53.87)	127.17	(2.81)
X	Other Comprehensive Income,	-	-	-	-
	Total Other Comprehensive Income, net of Tax	(99.92)	(53.87)	127.17	(2.81)
XI	Total Comprehensive Income for the period				
XII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2,258.63	2,258.63	2,258.63	2,258.63
XIII	Earning Per Share for the Period				
	Basic	-0.44	-0.24	0.56	-0.01
	Diluted	-0.44	-0.24	0.56	-0.01


Notes

- The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at it's meeting held on 14.08.2019
- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules , 2015 as amended from time to time.
- The Financial results and other financial information for the quarter ended 30th June,2019 has been compiled by the management as per Ind AS, after exercising necessary due diligence , to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any limited review or audit by any independent audit firm. The financial results are available in the form of annual report on the website of the Company. The financial results are available in the form of annual report on the website of the Company. The financial results are available in the form of annual report on the website of the Company.

HYDERABAD
Date: 14.08.2019

MANAGING DIRECTOR





B V SWAMI & CO.,

CHARTERED ACCOUNTANTS

Flat No. 101, Sridevi Apartments,
Hindi Nagar Colony, Punjagutta,
Hyderabad - 500 082.

Ph : 040-23350300

E-mail : cachandrasekharv@gmail.com
girishputha@gmail.com

LIMITED REVIEW REPORT

To
The Board of Directors,
Celestial Biolabs Limited

We have reviewed the accompanying "Statement of unaudited standalone financial results of M/s Celestial Biolabs Limited for quarter ended 30 June ,2019", being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 05, 2016.


The Preparation of Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, interim financial reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and read with SEBI Circular NO.CIR/CFD/FAC/62/2016 dated July 05, 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these Financial Statements based on our review.

We Conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial Results , prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 including the manner in which it is to be disclosed or that it contains any material misstatement.

For B V Swami & Co.,
Chartered Accountants
Firm Reg No. 009151S

CA. Chandrasekhar V
Partner
M.No. 223399



UDIN : 19223399AAAAAK6650
Place : Hyderabad
Date: 14.08.2019